SCHEMBL30346470

SCHEMBL30346470

FC1(F)CCC(Nc2ncc3c(-c4ccc5ncccc5c4)c[nH]c3n2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 6/20 0.51
▸ CLK2 P49760 3/20 0.51
▸ CLK3 P49761 2/20 0.51
▸ DYRK1B Q9Y463 2/20 0.42
▸ CLK1 P49759 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ BRD4 O60885 1/20 0.41
▸ RET P07949 4/20 0.40
▸ CDC7 O00311 6/20 0.40
▸ JAK2 O60674 2/20 0.40
▸ CCNB2 O95067 2/20 0.40
▸ MAP4K4 O95819 2/20 0.40
▸ INSR P06213 2/20 0.40
▸ CDK1 P06493 2/20 0.40
▸ CSF1R P07333 2/20 0.40
▸ PIM1 P11309 2/20 0.40
▸ CCNB1 P14635 2/20 0.40
▸ PRKACA P17612 2/20 0.40
▸ TYK2 P29597 2/20 0.40
▸ FLT3 P36888 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25157796 1.00 DYRK1A (0.51) DYRK1ACLK2CLK3DYRK1BCLK1
SCHEMBL30406904 0.90 DYRK1A (0.53) DYRK1ACLK2CLK3DYRK1BCLK1
SCHEMBL25157418 0.90 DYRK1A (0.53) DYRK1ACLK2CLK3DYRK1BCLK1
SCHEMBL30346467 0.89 BRD4 (0.41) DYRK1ACLK2CLK3DYRK1BBRD4
SCHEMBL25519916 0.89 BRD4 (0.41) DYRK1ACLK2CLK3DYRK1BBRD4
SCHEMBL25157324 0.88 DYRK1A (0.54) DYRK1ACLK2CLK3DYRK1BCLK1
SCHEMBL25519993 0.87 TDO2 (0.47) DYRK1ACLK2CLK3DYRK1BBRD4
SCHEMBL25157453 0.87 DYRK1A (0.55) DYRK1ACLK2CLK3DYRK1BCLK1
SCHEMBL30349016 0.87 DYRK1A (0.55) DYRK1ACLK2CLK3DYRK1BCLK1
SCHEMBL25158041 0.87 DYRK1A (0.55) DYRK1ACLK2CLK3DYRK1BCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback